Barbara Becattini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Barbara Becattini has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Solinas
The Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
15 shared publications Claudia Sardi
The Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
5 shared publications- Maurizio Pellecchia
Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, California 92037
5 shared publications - Ludovic Breasson
The Wallenberg Laboratory, Department of Molecular and Clinical Medicine at Institute of Medicine, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
4 shared publications - Angela Molinaro
University of Gothenburg
3 shared publications - Carsten Culmsee
Institute of Pharmacology and Clinical Pharmacy, University of Marburg, 35043 Marburg, Germany
3 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (7) , 101847
Loss of hepatocyte PI3Kα reduces hepatocellular carcinoma and hepatocyte proliferation in association with altered lipid metabolism
- 15 April 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (7) , 101847
Open AccessLoss of hepatocyte PI3Kα reduces hepatocellular carcinoma and hepatocyte proliferation in association with altered lipid metabolism
- Open Access
Ablation of PI3Kγ in neurons protects mice from diet-induced obesity MASLD and insulin resistance
- Open Access
- 10 June 2024
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 35 (6) , 466-477
An adipoincretin effect links adipostasis with insulin secretion
- 10 June 2024
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 35 (6) , 466-477
Open AccessAn adipoincretin effect links adipostasis with insulin secretion
- Open Access
Adipocyte PI3K Links Adipostasis with Basal Insulin Secretion Through an Adipoincretin Effect
SUMMARY: Insulin secretion is governed by insulin-PI3K signaling. Resolving the mechanism of this feedback is necessary to understand how insulin operates. Mice lacking the insulin receptor, or AKT1 and AKT2 in adipocytes, are severely lipoatrophic. Thus, the role of adipocyte insulin-PI3K signaling in the control of insulin secretion remains unknown. Using adipocyte- specific PI3Kα knockout mice (PI3Kα AdQ ) and a panel of isoform-selective PI3K inhibitors, we have found that PI3Kα and PI3Kβ activities are functionally redundant in adipocyte insulin signaling. PI3Kβ-selective inhibitors had no effect on adipocyte AKT phosphorylation in control mice but blunted AKT phosphorylation specifically in adipocytes of PI3Kα AdQ mice, demonstrating adipocyte-selective inhibition of PI3K signaling. Adipocyte-selective PI3K inhibition increased serum FFA and potently induced insulin secretion. We name this phenomenon the adipoincretin effect. The adipoincretin effect was dissociated from blood glucose and blood glucose counterregulatory response. The contribution of lipolysis, lipid, and amino acid metabolism, and selected adipokines to the adipoincretin effect has been investigated. We conclude that basal insulin secretion is chiefly controlled by adipocyte PI3K signaling through the adipoincretin effect. This phenomenon reveals an essential role for adipocyte insulin-PI3K signaling in linking the rates of adipose tissue lipolysis with baseline insulin secretion during fasting.
Open AccessAdipocyte PI3K Links Adipostasis with Basal Insulin Secretion Through an Adipoincretin Effect
SUMMARY: Insulin secretion is governed by insulin-PI3K signaling. Resolving the mechanism of this feedback is necessary to understand how insulin operates. Mice lacking the insulin receptor, or AKT1 and AKT2 in adipocytes, are severely lipoatrophic. Thus, the role of adipocyte insulin-PI3K signaling in the control of insulin secretion remains unknown. Using adipocyte- specific PI3Kα knockout mice (PI3Kα AdQ ) and a panel of isoform-selective PI3K inhibitors, we have found that PI3Kα and PI3Kβ activities are functionally redundant in adipocyte insulin signaling. PI3Kβ-selective inhibitors had no effect on adipocyte AKT phosphorylation in control mice but blunted AKT phosphorylation specifically in adipocytes of PI3Kα AdQ mice, demonstrating adipocyte-selective inhibition of PI3K signaling. Adipocyte-selective PI3K inhibition increased serum FFA and potently induced insulin secretion. We name this phenomenon the adipoincretin effect. The adipoincretin effect was dissociated from blood glucose and blood glucose counterregulatory response. The contribution of lipolysis, lipid, and amino acid metabolism, and selected adipokines to the adipoincretin effect has been investigated. We conclude that basal insulin secretion is chiefly controlled by adipocyte PI3K signaling through the adipoincretin effect. This phenomenon reveals an essential role for adipocyte insulin-PI3K signaling in linking the rates of adipose tissue lipolysis with baseline insulin secretion during fasting.
- Open Access
- 24 August 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (9) , e22512
Somatic ablation of IKKβ in liver and leukocytes is not tolerated in obese mice but hepatic IKKβ deletion improves fatty liver and insulin sensitivity
The kinase IKKβ controls pro‐inflammatory gene expression, and its activity in the liver and leukocytes was shown to drive metabolic inflammation and insulin resistance in obesity. However, it was also proposed that liver IKKβ signaling protects obese mice from insulin resistance and endoplasmic reticulum (ER) stress by increasing XBP1s protein stability. Furthermore, mice lacking IKKβ in leukocytes display increased lethality to lipopolysaccharides. This study aims at improving our understanding of the role of IKKβ signaling in obesity. We induced IKKβ deletion in hematopoietic cells and liver of obese mice by Cre‐LoxP recombination, using an INF‐inducible system, or a liver‐specific IKKβ deletion in obese mice by adenovirus delivery of the Cre recombinase. The histopathological, immune, and metabolic phenotype of the mice was characterized. IKKβ deletion in the liver and hematopoietic cells was not tolerated in mice with established obesity exposed to the TLR3 agonist poly(I:C) and exacerbated liver damage and ER‐stress despite elevated XBP1s. By contrast, liver‐specific ablation of IKKβ in obese mice reduced steatosis and improved insulin sensitivity in association with increased XBP1s protein abundance and reduced expression of de‐novo lipogenesis genes. We conclude that IKKβ blockage in liver and leukocytes is not tolerated in obese mice exposed to TLR3 agonists. However, selective hepatic IKKβ ablation improves fatty liver and insulin sensitivity in association with increased XBP1s protein abundance and reduced expression of lipogenic genes.
- 24 August 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (9) , e22512
Open AccessSomatic ablation of IKKβ in liver and leukocytes is not tolerated in obese mice but hepatic IKKβ deletion improves fatty liver and insulin sensitivity
The kinase IKKβ controls pro‐inflammatory gene expression, and its activity in the liver and leukocytes was shown to drive metabolic inflammation and insulin resistance in obesity. However, it was also proposed that liver IKKβ signaling protects obese mice from insulin resistance and endoplasmic reticulum (ER) stress by increasing XBP1s protein stability. Furthermore, mice lacking IKKβ in leukocytes display increased lethality to lipopolysaccharides. This study aims at improving our understanding of the role of IKKβ signaling in obesity. We induced IKKβ deletion in hematopoietic cells and liver of obese mice by Cre‐LoxP recombination, using an INF‐inducible system, or a liver‐specific IKKβ deletion in obese mice by adenovirus delivery of the Cre recombinase. The histopathological, immune, and metabolic phenotype of the mice was characterized. IKKβ deletion in the liver and hematopoietic cells was not tolerated in mice with established obesity exposed to the TLR3 agonist poly(I:C) and exacerbated liver damage and ER‐stress despite elevated XBP1s. By contrast, liver‐specific ablation of IKKβ in obese mice reduced steatosis and improved insulin sensitivity in association with increased XBP1s protein abundance and reduced expression of de‐novo lipogenesis genes. We conclude that IKKβ blockage in liver and leukocytes is not tolerated in obese mice exposed to TLR3 agonists. However, selective hepatic IKKβ ablation improves fatty liver and insulin sensitivity in association with increased XBP1s protein abundance and reduced expression of lipogenic genes.
- Top Cited PapersOpen Access
- 1 March 2021
- Published by Elsevier in EBioMedicine
- Vol. 65, 103264
Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study
- 1 March 2021
- Published by Elsevier in EBioMedicine
- Vol. 65, 103264
Top Cited PapersOpen AccessHyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study
- 1 June 2019
- Published by Elsevier in Cell Metabolism
- Vol. 29 (6) , 1400-1409.e5
Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS
- 1 June 2019
- Published by Elsevier in Cell Metabolism
- Vol. 29 (6) , 1400-1409.e5
Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS
- Open Access
- 25 October 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (63) , 106145-106146
The role of PI3Kγ in metabolism and macrophage activation
- 25 October 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (63) , 106145-106146
Open AccessThe role of PI3Kγ in metabolism and macrophage activation
- Open Access
- 13 September 2017
- Published by Wiley in The FASEB Journal
- Vol. 32 (1) , 319-329
PI3Kγ ablation does not promote diabetes in db/db mice, but improves insulin sensitivity and reduces pancreatic β‐cell apoptosis
PI3Kγ has emerged as a promising target for the treatment of obesity and insulin resistance; however, previous studies have indicated that PI3Kγ activity in pancreatic β cells is required for normal insulin secretion in response to glucose. Hence, a possible deterioration of insulin secretion capacity in patients who are predisposed to the failure of pancreatic β‐cell function is a major concern for the pharmacologic inhibition of PI3Kγ. To address this issue, we investigated the effects of PI3Kγ ablation in db/db diabetic mice, a genetic model of obesity‐driven β‐cell failure and diabetes. Mice that lacked PI3Kγ were backcrossed into db/+ mice C57BL/KS (>10 generations) to obtain db/db‐PI3Kγ‐/‐ mice. db/db‐PI3Kγ‐/‐ mice and control db/db mice were phenotyped for glucose homeostasis, insulin sensitivity, insulin secretion, steatosis, metabolic inflammation, pancreatic islet morphometry, islet cellular composition, and inflammation. Pancreatic p‐cell apoptosis and proliferation were also evaluated. db/db‐PI3K γ‐/‐ mice and control db/db mice developed similar body weight, steatosis, glycemia, and insulin levels after a glucose load; however, db/db‐PI3Kγ‐/‐ mice displayed improved insulin tolerance, higher levels of fasting serum insulin, and lower pancreatic insulin content. In db/db‐PI3Kγ‐/‐ mice, the number of adipose tissue macrophages was similar to control, but displayed reduced adipose tissue neutrophils and M2‐polarized adipose tissue gene expression. Finally, db/db‐PI3K γ‐/‐ mice have more pancreatic β cells and larger islets than db/db mice, despite displaying similar islet inflammation. This phenotype could be explained by reduced β‐cell apoptosis in db/db‐PI3K γ‐/‐ mice compared with control db/db mice. Our results are consistent with the concept that the beneficial action of PI3Kγ ablation in obesity‐driven glucose intolerance is largely a result of its leptin‐dependent effects on adiposity and, to a lesser extent, the promotion of adipose tissue neutrophil recruitment and M1 polarization of gene expression. Of importance, our data challenge the concept that PI3Kγ is required for insulin secretion in response to glucose in vivo , and indicate that PI3Kγ ablation protects db/db mice from β‐cell apoptosis and improves fasting insulin levels. We conclude that PI3Kγ inhibition in obese patients who are predisposed to β‐cell failure is not expected to produce adverse effects on insulin secretion.—Breasson, L., Sardi, C., Becattini, B., Zani, F., Solinas, G. PI3Kγ ablation does not promote diabetes in db/db mice, but improves insulin sensitivity and reduces pancreatic β‐cell apoptosis. FASEB J. 32, 319‐329 (2018). www.fasebj.org
- 13 September 2017
- Published by Wiley in The FASEB Journal
- Vol. 32 (1) , 319-329
Open AccessPI3Kγ ablation does not promote diabetes in db/db mice, but improves insulin sensitivity and reduces pancreatic β‐cell apoptosis
PI3Kγ has emerged as a promising target for the treatment of obesity and insulin resistance; however, previous studies have indicated that PI3Kγ activity in pancreatic β cells is required for normal insulin secretion in response to glucose. Hence, a possible deterioration of insulin secretion capacity in patients who are predisposed to the failure of pancreatic β‐cell function is a major concern for the pharmacologic inhibition of PI3Kγ. To address this issue, we investigated the effects of PI3Kγ ablation in db/db diabetic mice, a genetic model of obesity‐driven β‐cell failure and diabetes. Mice that lacked PI3Kγ were backcrossed into db/+ mice C57BL/KS (>10 generations) to obtain db/db‐PI3Kγ‐/‐ mice. db/db‐PI3Kγ‐/‐ mice and control db/db mice were phenotyped for glucose homeostasis, insulin sensitivity, insulin secretion, steatosis, metabolic inflammation, pancreatic islet morphometry, islet cellular composition, and inflammation. Pancreatic p‐cell apoptosis and proliferation were also evaluated. db/db‐PI3K γ‐/‐ mice and control db/db mice developed similar body weight, steatosis, glycemia, and insulin levels after a glucose load; however, db/db‐PI3Kγ‐/‐ mice displayed improved insulin tolerance, higher levels of fasting serum insulin, and lower pancreatic insulin content. In db/db‐PI3Kγ‐/‐ mice, the number of adipose tissue macrophages was similar to control, but displayed reduced adipose tissue neutrophils and M2‐polarized adipose tissue gene expression. Finally, db/db‐PI3K γ‐/‐ mice have more pancreatic β cells and larger islets than db/db mice, despite displaying similar islet inflammation. This phenotype could be explained by reduced β‐cell apoptosis in db/db‐PI3K γ‐/‐ mice compared with control db/db mice. Our results are consistent with the concept that the beneficial action of PI3Kγ ablation in obesity‐driven glucose intolerance is largely a result of its leptin‐dependent effects on adiposity and, to a lesser extent, the promotion of adipose tissue neutrophil recruitment and M1 polarization of gene expression. Of importance, our data challenge the concept that PI3Kγ is required for insulin secretion in response to glucose in vivo , and indicate that PI3Kγ ablation protects db/db mice from β‐cell apoptosis and improves fasting insulin levels. We conclude that PI3Kγ inhibition in obese patients who are predisposed to β‐cell failure is not expected to produce adverse effects on insulin secretion.—Breasson, L., Sardi, C., Becattini, B., Zani, F., Solinas, G. PI3Kγ ablation does not promote diabetes in db/db mice, but improves insulin sensitivity and reduces pancreatic β‐cell apoptosis. FASEB J. 32, 319‐329 (2018). www.fasebj.org
- 18 July 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (488)
PI3Kγ activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity
The kinase PI3Kγ aggravates obesity by activating macrophages and triggering inflammation in adipose tissue.
- 18 July 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (488)
PI3Kγ activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity
The kinase PI3Kγ aggravates obesity by activating macrophages and triggering inflammation in adipose tissue.